Summit Therapeutics Shares Rise 28% Following Positive Clinical Trial Results for Ivonescimab
Summit Therapeutics (NASDAQ:SMMT) experienced a significant surge in its share price, rising by nearly 28.19 percent week-on-week due to positive clinical trial results involving ivonescimab, the company's bispecific antibody candidate. The drug showed statistically significant improvements over pembrolizumab monotherapy for non-small cell lung cancer patients with PD-L1-positive tumors in a Phase 3 study conducted by its partner Akeso Inc. In addition to NSCLC, ivonescimab demonstrated promising results as part of a chemo-combination therapy for advanced biliary tract cancer. The regimen outperformed durvalumab-based treatment on key endpoints like overall survival and progression-free survival. Final data from these trials are expected at an upcoming medical conference. Despite the encouraging findings, ivonescimab remains in clinical development without regulatory approval yet. Investors should remain cautious as positive trial results do not guarantee commercial success or regulatory clearance.
Tickers: $SMMT
Topics: biliary tract cancer biopharmaceutical immunotherapy non-small cell lung cancer (NSCLC)